Showing 321 - 338 results of 338 for search '(((farr OR farry) OR (ftir OR pair)) OR far) 40', query time: 0.12s Refine Results
  1. 321

    Scaling up parametric human recovery by Cai, Zhongang

    Published 2024
    Get full text
    Thesis-Doctor of Philosophy
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326
  7. 327
  8. 328

    Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma by Howell, I, Yang, F, Brown, V, Cane, J, Marchi, E, Azim, A, Busby, J, McDowell, PJ, Diver, SE, Borg, C, Heaney, LG, Pavord, ID, Brightling, CE, Chaudhuri, R, Hinks, TSC

    Published 2024
    “…<p><b>Method</b></p> The MAPLE trial was a multi-centre, randomized, double-blind, placebo-controlled, crossover study of 2 weeks of high-dose oral prednisolone treatment at stable state in 27 patients treated with mepolizumab for SEA. We analysed paired sputum (n=16) and plasma (n=25) samples from the MAPLE trial using high-throughput Olink® proteomics. …”
    Journal article
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336

    Detection, characterisation and risk factor of Leptospira spp. among dogs and dog handlers by Goh, Soon Heng

    Published 2022
    “…In conclusion, MAT remains a gold standard test for serological diagnosis and surveillance, however, detailed considerations should be taken when interpreting results of clinical cases with the presence of anti-leptospiral antibodies, as paired serum for better interpretation was required. …”
    Get full text
    Thesis
  17. 337

    Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013:... by Forouzanfar, M, Alexander, L, Anderson, H, Ali, R, Beardsley, J, Bennett, D, Briggs, A, Chen, Z, Gething, P, Jha, V, Moschandreas, J, Newton, C, Rahimi, K, Scarborough, P

    Published 2015
    “…<p><strong>Findings</strong></p> All risks combined account for 57·2% (95% uncertainty interval [UI] 55·8–58·5) of deaths and 41·6% (40·1–43·0) of DALYs. Risks quantified account for 87·9% (86·5–89·3) of cardiovascular disease DALYs, ranging to a low of 0% for neonatal disorders and neglected tropical diseases and malaria. …”
    Journal article
  18. 338